ASCO 2015 Highlights

FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
By Yvette Florio Lane
Bladder Cancer, FDA Approvals, News & Updates, Immunotherapy
Web Exclusives
On December 2, 2019, Merck announced that the FDA has granted priority review for its supplemental biologics license application for the anti–PD-1 agent pembrolizumab (Keytruda).
Read Article
 Online First
Value-Based Care Management Medicare Program Changes for 2020 and Beyond
By Joseph S. Bailes, MD; Gena Cook
Economics & Value, Value-Based Care
December 2019, Vol 10, No 6
Medicare models for value-based care in oncology started with the Oncology Care Model (OCM), which was launched in July 2016 and will run until June 2021.
Read Article
November 25, 2019 – Oncology News & Updates
By Yvette Florio Lane
FDA Approvals, News & Updates, In the News, Leukemia, Lung Cancer, Lymphoma
Web Exclusives
Read Article

In This Article

  • Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
By Yvette Florio Lane
FDA Approvals, News & Updates, In the News
Web Exclusives
On November 15, 2019, the FDA approved crizanlizumab (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged ≥16 years with sickle-cell disease.
Read Article
Pharmacy’s Emerging Influence and the Roles Pharmacists Play
Pharmacy’s Emerging Influence and the Roles Pharmacists Play
Conference Correspondent
Leaders in oncology pharmacy tackle some of the biggest issues in the field today in a pre-summit professional development session.
Read Article
Cancer Centers and the Integrated Health Delivery Systems and the Cancer Care Value Perspectives
Cancer Centers and the Integrated Health Delivery Systems and the Cancer Care Value Perspectives
Conference Correspondent
Stakeholders address the challenge of integrating high-cost therapies into cancer care delivery.
Read Article

Page 87 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.